English

IMMUNE PHARMACEUTICALS INC.

EDGAR

IMNP Registration statement (S-1) · filed 2018-11-21

71 filing records in this dataset, filed from 2005-11-09 to 2018-11-21. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2018 Q3 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-1.5 million USD

2018 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -8344000 USD Source
Operating Cash Flow: -6849000 USD Source

Free cash flow

-1.53 million USD

2018 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -8344000 USD Source
Operating Cash Flow: -6849000 USD Source
Capital Expenditure: 99000 USD Source
Capital Expenditure: 61000 USD Source

Cash and cash equivalents: 76 thousand USD 2018-09-30 Source
Exact value

76000 USD
Long-term debt including current maturities: 9 million USD 2018-09-30 Source
Exact value

8997000 USD
Shares outstanding: 45 million shares 2018-09-30 Source
Exact value

44964491 shares

Reported share-count change

228.76% · 31.3 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

13676961 shares · 2017-09-30· Source
44964491 shares · 2018-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Operating cash flow

-14.7 million USD

2017-10-01 – 2018-09-30

Exact inputs and evidence

Operating cash flow: -11559000 USD · 2017-01-01 – 2017-12-31 Source
Operating cash flow: -5217000 USD · 2017-01-01 – 2017-09-30 Source
Operating cash flow: -3692000 USD · 2018-01-01 – 2018-03-31 Source
Operating cash flow: -6849000 USD · 2018-01-01 – 2018-06-30 Source
Operating cash flow: -3692000 USD · 2018-01-01 – 2018-03-31 Source
Operating cash flow: -8344000 USD · 2018-01-01 – 2018-09-30 Source
Operating cash flow: -6849000 USD · 2018-01-01 – 2018-06-30 Source

Capital expenditure

105 thousand USD

2017-10-01 – 2018-09-30

Exact inputs and evidence

Capital expenditure: 28000 USD · 2017-01-01 – 2017-12-31 Source
Capital expenditure: 22000 USD · 2017-01-01 – 2017-09-30 Source
Capital expenditure: 31000 USD · 2018-01-01 – 2018-03-31 Source
Capital expenditure: 61000 USD · 2018-01-01 – 2018-06-30 Source
Capital expenditure: 31000 USD · 2018-01-01 – 2018-03-31 Source
Capital expenditure: 99000 USD · 2018-01-01 – 2018-09-30 Source
Capital expenditure: 61000 USD · 2018-01-01 – 2018-06-30 Source

Free cash flow

-14.8 million USD

2017-10-01 – 2018-09-30

Exact inputs and evidence

Operating cash flow: -11559000 USD · 2017-01-01 – 2017-12-31 Source
Operating cash flow: -5217000 USD · 2017-01-01 – 2017-09-30 Source
Operating cash flow: -3692000 USD · 2018-01-01 – 2018-03-31 Source
Operating cash flow: -6849000 USD · 2018-01-01 – 2018-06-30 Source
Operating cash flow: -3692000 USD · 2018-01-01 – 2018-03-31 Source
Operating cash flow: -8344000 USD · 2018-01-01 – 2018-09-30 Source
Operating cash flow: -6849000 USD · 2018-01-01 – 2018-06-30 Source
Capital expenditure: 28000 USD · 2017-01-01 – 2017-12-31 Source
Capital expenditure: 22000 USD · 2017-01-01 – 2017-09-30 Source
Capital expenditure: 31000 USD · 2018-01-01 – 2018-03-31 Source
Capital expenditure: 61000 USD · 2018-01-01 – 2018-06-30 Source
Capital expenditure: 31000 USD · 2018-01-01 – 2018-03-31 Source
Capital expenditure: 99000 USD · 2018-01-01 – 2018-09-30 Source
Capital expenditure: 61000 USD · 2018-01-01 – 2018-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2018-11-21.

Financial data available through: 2017-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2017-12-31
Operating income: 11 of 11 periods available· newest 2017-12-31
Net income: 11 of 11 periods available· newest 2017-12-31
Operating cash flow: 11 of 11 periods available· newest 2017-12-31
Capital expenditure: 11 of 11 periods available· newest 2017-12-31
Total assets: 11 of 11 periods available· newest 2017-12-31
Total liabilities: 11 of 11 periods available· newest 2017-12-31
Current assets: 11 of 11 periods available· newest 2017-12-31
Current liabilities: 11 of 11 periods available· newest 2017-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2017-12-31
Long-term debt including current maturities: 6 of 11 periods available· newest 2017-12-31
Shares outstanding: 6 of 11 periods available· newest 2017-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
USD 0

Prior period

USD 0

2016-01-01 – 2016-12-31
Current period

USD 0

2017-01-01 – 2017-12-31

Exact inputs and evidence

0 − 0 = 0 USD

0 USD · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
0 USD · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · IMMUNE PHARMACEUTICALS INC. · 2017-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Year-over-year change in Revenue: 0 USD Concept: fundies:Revenue Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420418061227/imnp-20180930.xml#2507475 Filing: 000114420418061227 Input fundies:Revenue: 0 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420418061227/imnp-20180930.xml#2507599 Filing: 000114420418061227
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 14.77 million

Prior period

−USD 32.66 million

2016-01-01 – 2016-12-31
Current period

−USD 17.89 million

2017-01-01 – 2017-12-31

Exact inputs and evidence

-17889000 − -32661000 = 14772000 USD

-32661000 USD · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
-17889000 USD · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · IMMUNE PHARMACEUTICALS INC. · 2017-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Year-over-year change in Net income: 14772000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -17889000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420418061227/imnp-20180930.xml#4949091 Filing: 000114420418061227 Input fundies:NetIncome: -32661000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420418061227/imnp-20180930.xml#4922983 Filing: 000114420418061227
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 748,000

Prior period

−USD 12.31 million

2016-01-01 – 2016-12-31
Current period

−USD 11.56 million

2017-01-01 – 2017-12-31

Exact inputs and evidence

-11559000 − -12307000 = 748000 USD

-12307000 USD · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
-11559000 USD · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · IMMUNE PHARMACEUTICALS INC. · 2017-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Year-over-year change in Operating cash flow: 748000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -11559000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420418061227/imnp-20180930.xml#2714547 Filing: 000114420418061227 Input fundies:OperatingCashFlow: -12307000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420418061227/imnp-20180930.xml#2714747 Filing: 000114420418061227
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+33.3%

Prior period

USD 21,000

2016-01-01 – 2016-12-31
Current period

USD 28,000

2017-01-01 – 2017-12-31

Exact inputs and evidence

28000 − 21000 = 7000 USD

21000 USD · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
28000 USD · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · IMMUNE PHARMACEUTICALS INC. · 2017-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Year-over-year change in Capital expenditure: 7000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 28000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420418061227/imnp-20180930.xml#2715300 Filing: 000114420418061227 Input fundies:CapitalExpenditure: 21000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420418061227/imnp-20180930.xml#2715496 Filing: 000114420418061227
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2017 2017-01-01 – 2017-12-31

Revenue USD 0
Operating costs Derived USD 12.12 million
Operating income −USD 12.12 million
Tax, interest and other Derived USD 5.77 million
Net income −USD 17.89 million

Cash

Operating cash flow −USD 11.56 million
Capital expenditure USD 28,000
Free cash flow Derived −USD 11.59 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2008 Operating loss: operating costs were 8,386% of revenue.
2009 Operating loss: operating costs were 4,626% of revenue.
2010 Operating loss: operating costs were 1,647% of revenue.
2011 Operating loss: operating costs were 1,589% of revenue.
2012 Operating loss: operating costs were 218% of revenue.
2013 Operating loss: operating costs were 47,468% of revenue.
2014 Operating loss: operating costs were 818,250% of revenue.
2015 Not shown: operating income or net income is not reported.
2016 Not shown: operating income or net income is not reported.
2017 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2008 2008-01-01 – 2008-12-31	265000	22222000 Derived	-21957000	3425000 Derived	-25382000	-15674000 Derived	Source 2008-01-01 – 2008-12-31: 265000 USD Inspect Revenue Open source 2008-01-01 – 2008-12-31: -21957000 USD Inspect Operating Income Open source 2008-01-01 – 2008-12-31: -25382000 USD Inspect Net Income Open source 2008-01-01 – 2008-12-31: -15637000 USD Inspect Operating Cash Flow Open source 2008-01-01 – 2008-12-31: 37000 USD Inspect Capital Expenditure Open source
2009 2009-01-01 – 2009-12-31	414000	19151000 Derived	-18737000	20077000 Derived	-38814000	-29480000 Derived	Source 2009-01-01 – 2009-12-31: 414000 USD Inspect Revenue Open source 2009-01-01 – 2009-12-31: -18737000 USD Inspect Operating Income Open source 2009-01-01 – 2009-12-31: -38814000 USD Inspect Net Income Open source 2009-01-01 – 2009-12-31: -29453000 USD Inspect Operating Cash Flow Open source 2009-01-01 – 2009-12-31: 27000 USD Inspect Capital Expenditure Open source
2010 2010-01-01 – 2010-12-31	994000	16368000 Derived	-15374000	-14479000 Derived	-895000	-10402000 Derived	Source 2010-01-01 – 2010-12-31: 994000 USD Inspect Revenue Open source 2010-01-01 – 2010-12-31: -15374000 USD Inspect Operating Income Open source 2010-01-01 – 2010-12-31: -895000 USD Inspect Net Income Open source 2010-01-01 – 2010-12-31: -10400000 USD Inspect Operating Cash Flow Open source 2010-01-01 – 2010-12-31: 2000 USD Inspect Capital Expenditure Open source
2011 2011-01-01 – 2011-12-31	944000	14997000 Derived	-14053000	-11936000 Derived	-2117000	-14028000 Derived	Source 2011-01-01 – 2011-12-31: 944000 USD Inspect Revenue Open source 2011-01-01 – 2011-12-31: -14053000 USD Inspect Operating Income Open source 2011-01-01 – 2011-12-31: -2117000 USD Inspect Net Income Open source 2011-01-01 – 2011-12-31: -14002000 USD Inspect Operating Cash Flow Open source 2011-01-01 – 2011-12-31: 26000 USD Inspect Capital Expenditure Open source
2012 2012-01-01 – 2012-12-31	7804000	16996000 Derived	-9192000	3383000 Derived	-12575000	-2846000 Derived	Source 2012-01-01 – 2012-12-31: 7804000 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: -9192000 USD Inspect Operating Income Open source 2012-01-01 – 2012-12-31: -12575000 USD Inspect Net Income Open source 2012-01-01 – 2012-12-31: -2820000 USD Inspect Operating Cash Flow Open source 2012-01-01 – 2012-12-31: 26000 USD Inspect Capital Expenditure Open source
2013 2013-01-01 – 2013-12-31	19000	9019000 Derived	-9000000	-3240000 Derived	-5760000	-3868000 Derived	Source 2013-01-01 – 2013-12-31: 19000 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -9000000 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -5760000 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: -3868000 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 0 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	2000	16365000 Derived	-16363000	7187000 Derived	-23550000	-13887000 Derived	Source 2014-01-01 – 2014-12-31: 2000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -16363000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -23550000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -13864000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 23000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	0	15724000 Derived	-15724000	1433000 Derived	-17157000	-14073000 Derived	Source 2015-01-01 – 2015-12-31: 0 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -15724000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -17157000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -13906000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 167000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	0	27260000 Derived	-27260000	5401000 Derived	-32661000	-12328000 Derived	Source 2016-01-01 – 2016-12-31: 0 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -27260000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -32661000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -12307000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 21000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	0	12123000 Derived	-12123000	5766000 Derived	-17889000	-11587000 Derived	Source 2017-01-01 – 2017-12-31: 0 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -12123000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -17889000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -11559000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 28000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2017

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20082008-12-31	Revenue	265000	Revenue: 265000 Open source
20092009-12-31	Revenue	414000	Revenue: 414000 Open source
20102010-12-31	Revenue	994000	Revenue: 994000 Open source
20112011-12-31	Revenue	944000	Revenue: 944000 Open source
20122012-12-31	Revenue	7804000	Revenue: 7804000 Open source
20132013-12-31	Revenue	19000	Revenue: 19000 Open source
20142014-12-31	Revenue	2000	Revenue: 2000 Open source
20152015-12-31	Revenue	0	Revenue: 0 Open source
20162016-12-31	Revenue	0	Revenue: 0 Open source
20172017-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2015

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20082008-12-31	Year over year	-19%	Revenue: 265000 Open source Revenue: 327000 Open source
20092009-12-31	Year over year	56.2%	Revenue: 414000 Open source Revenue: 265000 Open source
20102010-12-31	Year over year	140.1%	Revenue: 994000 Open source Revenue: 414000 Open source
20112011-12-31	Year over year	-5%	Revenue: 944000 Open source Revenue: 994000 Open source
20122012-12-31	Year over year	726.7%	Revenue: 7804000 Open source Revenue: 944000 Open source
20132013-12-31	Year over year	-99.8%	Revenue: 19000 Open source Revenue: 7804000 Open source
20142014-12-31	Year over year	-89.5%	Revenue: 2000 Open source Revenue: 19000 Open source
20152015-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 2000 Open source
20162016-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20172017-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -818,150% 2014

Net margin -1,177,500% 2014

Free cash flow margin -694,350% 2014

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20082008-12-31	Operating margin	-8,285.7%	Operating Income: -21957000 Open source Revenue: 265000 Open source
20092009-12-31	Operating margin	-4,525.8%	Operating Income: -18737000 Open source Revenue: 414000 Open source
20102010-12-31	Operating margin	-1,546.7%	Operating Income: -15374000 Open source Revenue: 994000 Open source
20112011-12-31	Operating margin	-1,488.7%	Operating Income: -14053000 Open source Revenue: 944000 Open source
20122012-12-31	Operating margin	-117.8%	Operating Income: -9192000 Open source Revenue: 7804000 Open source
20132013-12-31	Operating margin	-47,368.4%	Operating Income: -9000000 Open source Revenue: 19000 Open source
20142014-12-31	Operating margin	-818,150%	Operating Income: -16363000 Open source Revenue: 2000 Open source
20152015-12-31	Operating margin	Not reported	Operating Income: -15724000 Open source Revenue: 0 Open source
20162016-12-31	Operating margin	Not reported	Operating Income: -27260000 Open source Revenue: 0 Open source
20172017-12-31	Operating margin	Not reported	Operating Income: -12123000 Open source Revenue: 0 Open source
20082008-12-31	Net margin	-9,578.1%	Net Income: -25382000 Open source Revenue: 265000 Open source
20092009-12-31	Net margin	-9,375.4%	Net Income: -38814000 Open source Revenue: 414000 Open source
20102010-12-31	Net margin	-90%	Net Income: -895000 Open source Revenue: 994000 Open source
20112011-12-31	Net margin	-224.3%	Net Income: -2117000 Open source Revenue: 944000 Open source
20122012-12-31	Net margin	-161.1%	Net Income: -12575000 Open source Revenue: 7804000 Open source
20132013-12-31	Net margin	-30,315.8%	Net Income: -5760000 Open source Revenue: 19000 Open source
20142014-12-31	Net margin	-1,177,500%	Net Income: -23550000 Open source Revenue: 2000 Open source
20152015-12-31	Net margin	Not reported	Net Income: -17157000 Open source Revenue: 0 Open source
20162016-12-31	Net margin	Not reported	Net Income: -32661000 Open source Revenue: 0 Open source
20172017-12-31	Net margin	Not reported	Net Income: -17889000 Open source Revenue: 0 Open source
20082008-12-31	Free cash flow margin	-5,914.7%	Revenue: 265000 Open source Operating Cash Flow: -15637000 Open source Capital Expenditure: 37000 Open source
20092009-12-31	Free cash flow margin	-7,120.8%	Revenue: 414000 Open source Operating Cash Flow: -29453000 Open source Capital Expenditure: 27000 Open source
20102010-12-31	Free cash flow margin	-1,046.5%	Revenue: 994000 Open source Operating Cash Flow: -10400000 Open source Capital Expenditure: 2000 Open source
20112011-12-31	Free cash flow margin	-1,486%	Revenue: 944000 Open source Operating Cash Flow: -14002000 Open source Capital Expenditure: 26000 Open source
20122012-12-31	Free cash flow margin	-36.5%	Revenue: 7804000 Open source Operating Cash Flow: -2820000 Open source Capital Expenditure: 26000 Open source
20132013-12-31	Free cash flow margin	-20,357.9%	Revenue: 19000 Open source Operating Cash Flow: -3868000 Open source Capital Expenditure: 0 Open source
20142014-12-31	Free cash flow margin	-694,350%	Revenue: 2000 Open source Operating Cash Flow: -13864000 Open source Capital Expenditure: 23000 Open source
20152015-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -13906000 Open source Capital Expenditure: 167000 Open source
20162016-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -12307000 Open source Capital Expenditure: 21000 Open source
20172017-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -11559000 Open source Capital Expenditure: 28000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -11.6M 2017

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20082008-12-31	Operating cash flow	-15637000	Operating Cash Flow: -15637000 Open source
20092009-12-31	Operating cash flow	-29453000	Operating Cash Flow: -29453000 Open source
20102010-12-31	Operating cash flow	-10400000	Operating Cash Flow: -10400000 Open source
20112011-12-31	Operating cash flow	-14002000	Operating Cash Flow: -14002000 Open source
20122012-12-31	Operating cash flow	-2820000	Operating Cash Flow: -2820000 Open source
20132013-12-31	Operating cash flow	-3868000	Operating Cash Flow: -3868000 Open source
20142014-12-31	Operating cash flow	-13864000	Operating Cash Flow: -13864000 Open source
20152015-12-31	Operating cash flow	-13906000	Operating Cash Flow: -13906000 Open source
20162016-12-31	Operating cash flow	-12307000	Operating Cash Flow: -12307000 Open source
20172017-12-31	Operating cash flow	-11559000	Operating Cash Flow: -11559000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -11.6M 2017

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20082008-12-31	Free cash flow	-15674000	Operating Cash Flow: -15637000 Open source Capital Expenditure: 37000 Open source
20092009-12-31	Free cash flow	-29480000	Operating Cash Flow: -29453000 Open source Capital Expenditure: 27000 Open source
20102010-12-31	Free cash flow	-10402000	Operating Cash Flow: -10400000 Open source Capital Expenditure: 2000 Open source
20112011-12-31	Free cash flow	-14028000	Operating Cash Flow: -14002000 Open source Capital Expenditure: 26000 Open source
20122012-12-31	Free cash flow	-2846000	Operating Cash Flow: -2820000 Open source Capital Expenditure: 26000 Open source
20132013-12-31	Free cash flow	-3868000	Operating Cash Flow: -3868000 Open source Capital Expenditure: 0 Open source
20142014-12-31	Free cash flow	-13887000	Operating Cash Flow: -13864000 Open source Capital Expenditure: 23000 Open source
20152015-12-31	Free cash flow	-14073000	Operating Cash Flow: -13906000 Open source Capital Expenditure: 167000 Open source
20162016-12-31	Free cash flow	-12328000	Operating Cash Flow: -12307000 Open source Capital Expenditure: 21000 Open source
20172017-12-31	Free cash flow	-11587000	Operating Cash Flow: -11559000 Open source Capital Expenditure: 28000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

51.9% 2017

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20082008-12-31	Liabilities / assets	880.7%	Total Liabilities: 20001000 Open source Total Assets: 2271000 Open source
20092009-12-31	Liabilities / assets	220.8%	Total Liabilities: 16593000 Open source Total Assets: 7514000 Open source
20102010-12-31	Liabilities / assets	401.5%	Total Liabilities: 18824000 Open source Total Assets: 4689000 Open source
20112011-12-31	Liabilities / assets	328%	Total Liabilities: 24667000 Open source Total Assets: 7521000 Open source
20122012-12-31	Liabilities / assets	99.7%	Total Liabilities: 4117000 Open source Total Assets: 4131000 Open source
20132013-12-31	Liabilities / assets	82.6%	Total Liabilities: 26018000 Open source Total Assets: 31501000 Open source
20142014-12-31	Liabilities / assets	53.7%	Total Liabilities: 20320000 Open source Total Assets: 37864000 Open source
20152015-12-31	Liabilities / assets	73.7%	Total Liabilities: 26662000 Open source Total Assets: 36184000 Open source
20162016-12-31	Liabilities / assets	86.8%	Total Liabilities: 16592000 Open source Total Assets: 19105000 Open source
20172017-12-31	Liabilities / assets	51.9%	Total Liabilities: 14850000 Open source Total Assets: 28608000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.76× 2017

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20082008-12-31	Current assets / current liabilities	0.12×	Current Assets: 1185000 Open source Current Liabilities: 9720000 Open source
20092009-12-31	Current assets / current liabilities	1.26×	Current Assets: 6871000 Open source Current Liabilities: 5464000 Open source
20102010-12-31	Current assets / current liabilities	0.61×	Current Assets: 2947000 Open source Current Liabilities: 4834000 Open source
20112011-12-31	Current assets / current liabilities	0.55×	Current Assets: 6737000 Open source Current Liabilities: 12237000 Open source
20122012-12-31	Current assets / current liabilities	0.04×	Current Assets: 116000 Open source Current Liabilities: 3303000 Open source
20132013-12-31	Current assets / current liabilities	0.02×	Current Assets: 267000 Open source Current Liabilities: 11268000 Open source
20142014-12-31	Current assets / current liabilities	0.93×	Current Assets: 6887000 Open source Current Liabilities: 7417000 Open source
20152015-12-31	Current assets / current liabilities	0.77×	Current Assets: 4832000 Open source Current Liabilities: 6286000 Open source
20162016-12-31	Current assets / current liabilities	0.07×	Current Assets: 644000 Open source Current Liabilities: 9165000 Open source
20172017-12-31	Current assets / current liabilities	0.76×	Current Assets: 7031000 Open source Current Liabilities: 9251000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2008 2008-01-01 – 2008-12-31	−USD 25.38 million Exact value Exact value: -25382000 USD 2008-01-01 – 2008-12-31: -25382000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IMMUNE PHARMACEUTICALS INC. · 2008-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Net Income: -25382000 USD Concept: fundies:NetIncome Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3ANetIncome&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:NetIncome: -25382000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/0000950123-11-031166.txt#12832 The citation records this snapshot. The page link may show a newer release later.	−USD 15.64 million Exact value Exact value: -15637000 USD 2008-01-01 – 2008-12-31: -15637000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IMMUNE PHARMACEUTICALS INC. · 2008-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Operating Cash Flow: -15637000 USD Concept: fundies:OperatingCashFlow Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3AOperatingCashFlow&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15637000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/0000950123-11-031166.txt#13144 The citation records this snapshot. The page link may show a newer release later.	USD 37,000 Exact value Exact value: 37000 USD 2008-01-01 – 2008-12-31: 37000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IMMUNE PHARMACEUTICALS INC. · 2008-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Capital Expenditure: 37000 USD Concept: fundies:CapitalExpenditure Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3ACapitalExpenditure&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 37000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/0000950123-11-031166.txt#13232 The citation records this snapshot. The page link may show a newer release later.	−USD 15.67 million Calculation and evidence -15637000 − 37000 USD Exact free cash flow: -15674000 USD 2008-01-01 – 2008-12-31: -15637000 USD · Inspect Operating Cash Flow · Source 2008-01-01 – 2008-12-31: 37000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IMMUNE PHARMACEUTICALS INC. · 2008-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Free cash flow: -15674000 USD Concept: free-cash-flow Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15637000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/0000950123-11-031166.txt#13144 Input fundies:CapitalExpenditure: 37000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/0000950123-11-031166.txt#13232 The citation records this snapshot. The page link may show a newer release later.
2009 2009-01-01 – 2009-12-31	−USD 38.81 million Exact value Exact value: -38814000 USD 2009-01-01 – 2009-12-31: -38814000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IMMUNE PHARMACEUTICALS INC. · 2009-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Net Income: -38814000 USD Concept: fundies:NetIncome Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3ANetIncome&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:NetIncome: -38814000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/0000950123-11-031166.txt#12832 The citation records this snapshot. The page link may show a newer release later.	−USD 29.45 million Exact value Exact value: -29453000 USD 2009-01-01 – 2009-12-31: -29453000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IMMUNE PHARMACEUTICALS INC. · 2009-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Operating Cash Flow: -29453000 USD Concept: fundies:OperatingCashFlow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3AOperatingCashFlow&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -29453000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000110465912022842/epct-20111231.xml#25195 Filing: 000110465912022842 The citation records this snapshot. The page link may show a newer release later.	USD 27,000 Exact value Exact value: 27000 USD 2009-01-01 – 2009-12-31: 27000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IMMUNE PHARMACEUTICALS INC. · 2009-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Capital Expenditure: 27000 USD Concept: fundies:CapitalExpenditure Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3ACapitalExpenditure&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 27000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000110465912022842/epct-20111231.xml#30343 Filing: 000110465912022842 The citation records this snapshot. The page link may show a newer release later.	−USD 29.48 million Calculation and evidence -29453000 − 27000 USD Exact free cash flow: -29480000 USD 2009-01-01 – 2009-12-31: -29453000 USD · Inspect Operating Cash Flow · Source 2009-01-01 – 2009-12-31: 27000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IMMUNE PHARMACEUTICALS INC. · 2009-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Free cash flow: -29480000 USD Concept: free-cash-flow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -29453000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000110465912022842/epct-20111231.xml#25195 Filing: 000110465912022842 Input fundies:CapitalExpenditure: 27000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000110465912022842/epct-20111231.xml#30343 Filing: 000110465912022842 The citation records this snapshot. The page link may show a newer release later.
2010 2010-01-01 – 2010-12-31	−USD 895,000 Exact value Exact value: -895000 USD 2010-01-01 – 2010-12-31: -895000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IMMUNE PHARMACEUTICALS INC. · 2010-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Net Income: -895000 USD Concept: fundies:NetIncome Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3ANetIncome&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:NetIncome: -895000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000143774913015039/imnp-20130930.xml#327965 Filing: 000143774913015039 The citation records this snapshot. The page link may show a newer release later.	−USD 10.4 million Exact value Exact value: -10400000 USD 2010-01-01 – 2010-12-31: -10400000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IMMUNE PHARMACEUTICALS INC. · 2010-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Operating Cash Flow: -10400000 USD Concept: fundies:OperatingCashFlow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3AOperatingCashFlow&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10400000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000110465912022842/epct-20111231.xml#24980 Filing: 000110465912022842 The citation records this snapshot. The page link may show a newer release later.	USD 2,000 Exact value Exact value: 2000 USD 2010-01-01 – 2010-12-31: 2000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IMMUNE PHARMACEUTICALS INC. · 2010-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Capital Expenditure: 2000 USD Concept: fundies:CapitalExpenditure Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3ACapitalExpenditure&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000110465912022842/epct-20111231.xml#30173 Filing: 000110465912022842 The citation records this snapshot. The page link may show a newer release later.	−USD 10.4 million Calculation and evidence -10400000 − 2000 USD Exact free cash flow: -10402000 USD 2010-01-01 – 2010-12-31: -10400000 USD · Inspect Operating Cash Flow · Source 2010-01-01 – 2010-12-31: 2000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IMMUNE PHARMACEUTICALS INC. · 2010-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Free cash flow: -10402000 USD Concept: free-cash-flow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10400000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000110465912022842/epct-20111231.xml#24980 Filing: 000110465912022842 Input fundies:CapitalExpenditure: 2000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000110465912022842/epct-20111231.xml#30173 Filing: 000110465912022842 The citation records this snapshot. The page link may show a newer release later.
2011 2011-01-01 – 2011-12-31	−USD 2.12 million Exact value Exact value: -2117000 USD 2011-01-01 – 2011-12-31: -2117000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IMMUNE PHARMACEUTICALS INC. · 2011-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Net Income: -2117000 USD Concept: fundies:NetIncome Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3ANetIncome&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2117000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000143774914006363/imnp-20131231.xml#356002 Filing: 000143774914006363 The citation records this snapshot. The page link may show a newer release later.	−USD 14 million Exact value Exact value: -14002000 USD 2011-01-01 – 2011-12-31: -14002000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IMMUNE PHARMACEUTICALS INC. · 2011-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Operating Cash Flow: -14002000 USD Concept: fundies:OperatingCashFlow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3AOperatingCashFlow&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14002000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000110465913017543/epct-20121231.xml#162755 Filing: 000110465913017543 The citation records this snapshot. The page link may show a newer release later.	USD 26,000 Exact value Exact value: 26000 USD 2011-01-01 – 2011-12-31: 26000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IMMUNE PHARMACEUTICALS INC. · 2011-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Capital Expenditure: 26000 USD Concept: fundies:CapitalExpenditure Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3ACapitalExpenditure&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 26000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000110465913017543/epct-20121231.xml#163560 Filing: 000110465913017543 The citation records this snapshot. The page link may show a newer release later.	−USD 14.03 million Calculation and evidence -14002000 − 26000 USD Exact free cash flow: -14028000 USD 2011-01-01 – 2011-12-31: -14002000 USD · Inspect Operating Cash Flow · Source 2011-01-01 – 2011-12-31: 26000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IMMUNE PHARMACEUTICALS INC. · 2011-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Free cash flow: -14028000 USD Concept: free-cash-flow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14002000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000110465913017543/epct-20121231.xml#162755 Filing: 000110465913017543 Input fundies:CapitalExpenditure: 26000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000110465913017543/epct-20121231.xml#163560 Filing: 000110465913017543 The citation records this snapshot. The page link may show a newer release later.
2012 2012-01-01 – 2012-12-31	−USD 12.58 million Exact value Exact value: -12575000 USD 2012-01-01 – 2012-12-31: -12575000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IMMUNE PHARMACEUTICALS INC. · 2012-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Net Income: -12575000 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12575000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000143774914006363/imnp-20131231.xml#345458 Filing: 000143774914006363 The citation records this snapshot. The page link may show a newer release later.	−USD 2.82 million Exact value Exact value: -2820000 USD 2012-01-01 – 2012-12-31: -2820000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IMMUNE PHARMACEUTICALS INC. · 2012-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Operating Cash Flow: -2820000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2820000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000143774914006363/imnp-20131231.xml#379295 Filing: 000143774914006363 The citation records this snapshot. The page link may show a newer release later.	USD 26,000 Exact value Exact value: 26000 USD 2012-01-01 – 2012-12-31: 26000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IMMUNE PHARMACEUTICALS INC. · 2012-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Capital Expenditure: 26000 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 26000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000143774914006363/imnp-20131231.xml#380789 Filing: 000143774914006363 The citation records this snapshot. The page link may show a newer release later.	−USD 2.85 million Calculation and evidence -2820000 − 26000 USD Exact free cash flow: -2846000 USD 2012-01-01 – 2012-12-31: -2820000 USD · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 26000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IMMUNE PHARMACEUTICALS INC. · 2012-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Free cash flow: -2846000 USD Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -2820000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000143774914006363/imnp-20131231.xml#379295 Filing: 000143774914006363 Input fundies:CapitalExpenditure: 26000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000143774914006363/imnp-20131231.xml#380789 Filing: 000143774914006363 The citation records this snapshot. The page link may show a newer release later.
2013 2013-01-01 – 2013-12-31	−USD 5.76 million Exact value Exact value: -5760000 USD 2013-01-01 – 2013-12-31: -5760000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IMMUNE PHARMACEUTICALS INC. · 2013-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Net Income: -5760000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5760000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420415023077/imnp-20141231.xml#1351972 Filing: 000114420415023077 The citation records this snapshot. The page link may show a newer release later.	−USD 3.87 million Exact value Exact value: -3868000 USD 2013-01-01 – 2013-12-31: -3868000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IMMUNE PHARMACEUTICALS INC. · 2013-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Operating Cash Flow: -3868000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3868000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420415023077/imnp-20141231.xml#1555913 Filing: 000114420415023077 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2013-01-01 – 2013-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IMMUNE PHARMACEUTICALS INC. · 2013-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420415023077/imnp-20141231.xml#1556991 Filing: 000114420415023077 The citation records this snapshot. The page link may show a newer release later.	−USD 3.87 million Calculation and evidence -3868000 − 0 USD Exact free cash flow: -3868000 USD 2013-01-01 – 2013-12-31: -3868000 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IMMUNE PHARMACEUTICALS INC. · 2013-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Free cash flow: -3868000 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3868000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420415023077/imnp-20141231.xml#1555913 Filing: 000114420415023077 Input fundies:CapitalExpenditure: 0 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420415023077/imnp-20141231.xml#1556991 Filing: 000114420415023077 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 23.55 million Exact value Exact value: -23550000 USD 2014-01-01 – 2014-12-31: -23550000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IMMUNE PHARMACEUTICALS INC. · 2014-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Net Income: -23550000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -23550000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420416091621/imnp-20151231.xml#312234 Filing: 000114420416091621 The citation records this snapshot. The page link may show a newer release later.	−USD 13.86 million Exact value Exact value: -13864000 USD 2014-01-01 – 2014-12-31: -13864000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IMMUNE PHARMACEUTICALS INC. · 2014-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Operating Cash Flow: -13864000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13864000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420416091621/imnp-20151231.xml#317889 Filing: 000114420416091621 The citation records this snapshot. The page link may show a newer release later.	USD 23,000 Exact value Exact value: 23000 USD 2014-01-01 – 2014-12-31: 23000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IMMUNE PHARMACEUTICALS INC. · 2014-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Capital Expenditure: 23000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 23000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420416091621/imnp-20151231.xml#318639 Filing: 000114420416091621 The citation records this snapshot. The page link may show a newer release later.	−USD 13.89 million Calculation and evidence -13864000 − 23000 USD Exact free cash flow: -13887000 USD 2014-01-01 – 2014-12-31: -13864000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 23000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IMMUNE PHARMACEUTICALS INC. · 2014-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Free cash flow: -13887000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13864000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420416091621/imnp-20151231.xml#317889 Filing: 000114420416091621 Input fundies:CapitalExpenditure: 23000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420416091621/imnp-20151231.xml#318639 Filing: 000114420416091621 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 17.16 million Exact value Exact value: -17157000 USD 2015-01-01 – 2015-12-31: -17157000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IMMUNE PHARMACEUTICALS INC. · 2015-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Net Income: -17157000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17157000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420417028202/imnp-20161231.xml#194638 Filing: 000114420417028202 The citation records this snapshot. The page link may show a newer release later.	−USD 13.91 million Exact value Exact value: -13906000 USD 2015-01-01 – 2015-12-31: -13906000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IMMUNE PHARMACEUTICALS INC. · 2015-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Operating Cash Flow: -13906000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13906000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420417028202/imnp-20161231.xml#215360 Filing: 000114420417028202 The citation records this snapshot. The page link may show a newer release later.	USD 167,000 Exact value Exact value: 167000 USD 2015-01-01 – 2015-12-31: 167000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IMMUNE PHARMACEUTICALS INC. · 2015-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Capital Expenditure: 167000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 167000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420417028202/imnp-20161231.xml#216104 Filing: 000114420417028202 The citation records this snapshot. The page link may show a newer release later.	−USD 14.07 million Calculation and evidence -13906000 − 167000 USD Exact free cash flow: -14073000 USD 2015-01-01 – 2015-12-31: -13906000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 167000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IMMUNE PHARMACEUTICALS INC. · 2015-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Free cash flow: -14073000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13906000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420417028202/imnp-20161231.xml#215360 Filing: 000114420417028202 Input fundies:CapitalExpenditure: 167000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420417028202/imnp-20161231.xml#216104 Filing: 000114420417028202 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 32.66 million Exact value Exact value: -32661000 USD 2016-01-01 – 2016-12-31: -32661000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IMMUNE PHARMACEUTICALS INC. · 2016-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Net Income: -32661000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -32661000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420418061227/imnp-20180930.xml#4922983 Filing: 000114420418061227 The citation records this snapshot. The page link may show a newer release later.	−USD 12.31 million Exact value Exact value: -12307000 USD 2016-01-01 – 2016-12-31: -12307000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IMMUNE PHARMACEUTICALS INC. · 2016-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Operating Cash Flow: -12307000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12307000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420418061227/imnp-20180930.xml#2714747 Filing: 000114420418061227 The citation records this snapshot. The page link may show a newer release later.	USD 21,000 Exact value Exact value: 21000 USD 2016-01-01 – 2016-12-31: 21000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IMMUNE PHARMACEUTICALS INC. · 2016-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Capital Expenditure: 21000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 21000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420418061227/imnp-20180930.xml#2715496 Filing: 000114420418061227 The citation records this snapshot. The page link may show a newer release later.	−USD 12.33 million Calculation and evidence -12307000 − 21000 USD Exact free cash flow: -12328000 USD 2016-01-01 – 2016-12-31: -12307000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 21000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IMMUNE PHARMACEUTICALS INC. · 2016-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Free cash flow: -12328000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12307000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420418061227/imnp-20180930.xml#2714747 Filing: 000114420418061227 Input fundies:CapitalExpenditure: 21000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420418061227/imnp-20180930.xml#2715496 Filing: 000114420418061227 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 17.89 million Exact value Exact value: -17889000 USD 2017-01-01 – 2017-12-31: -17889000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IMMUNE PHARMACEUTICALS INC. · 2017-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Net Income: -17889000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17889000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420418061227/imnp-20180930.xml#4949091 Filing: 000114420418061227 The citation records this snapshot. The page link may show a newer release later.	−USD 11.56 million Exact value Exact value: -11559000 USD 2017-01-01 – 2017-12-31: -11559000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IMMUNE PHARMACEUTICALS INC. · 2017-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Operating Cash Flow: -11559000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -11559000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420418061227/imnp-20180930.xml#2714547 Filing: 000114420418061227 The citation records this snapshot. The page link may show a newer release later.	USD 28,000 Exact value Exact value: 28000 USD 2017-01-01 – 2017-12-31: 28000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IMMUNE PHARMACEUTICALS INC. · 2017-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Capital Expenditure: 28000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 28000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420418061227/imnp-20180930.xml#2715300 Filing: 000114420418061227 The citation records this snapshot. The page link may show a newer release later.	−USD 11.59 million Calculation and evidence -11559000 − 28000 USD Exact free cash flow: -11587000 USD 2017-01-01 – 2017-12-31: -11559000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 28000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IMMUNE PHARMACEUTICALS INC. · 2017-12-31 IMMUNE PHARMACEUTICALS INC. (edgar:1208261) Free cash flow: -11587000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:25:32Z Snapshot: 06707ace716cc7f56e980627da7ecaed6368503cd771cf4c0022256bea68faeb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1208261?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -11559000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420418061227/imnp-20180930.xml#2714547 Filing: 000114420418061227 Input fundies:CapitalExpenditure: 28000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1208261/000114420418061227/imnp-20180930.xml#2715300 Filing: 000114420418061227 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

71 filings · 2,238 latest values · 2,249 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001208261, 1208261, IMNP, edgar:1208261

Also known as EPICEPT CORP, IMMUNE PHARMACEUTICALS INC, IMMUNE PHARMACEUTICALS INC.

IMMUNE PHARMACEUTICALS INC.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2017 2017-01-01 – 2017-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation